GSK Blood Cancer Drug Setback - Search News

Order byBest matchMost fresh

News

GSK, FDA and Drug Administration

· 1d · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

Continue reading

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

· 1d · on MSN

GSK falls as blood cancer drug likely headed for US rejection

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GlobalData on MSN1d

FDA approves GSK’s prefilled syringe presentation of Shingrix

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results